Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 The California ... research organization representing leading California academic institutions, biotechnology, ... PwC US today released a report revealing ... industry growth. The trend shows a 4 percent ... California Biomedical Industry Report indicates that, while ...
(Date:11/21/2014)... 20, 2014 BlueInGreen, LLC ( ... LLC (Pinnacle), and PCI, Inc., leading suppliers of ... have been selected to provide a new state-of-the-art ... Paul R. Noland Wastewater Treatment. The new ... HyDOZ® gas dissolution technology, Pinnacle Ozone’s industry ...
(Date:11/21/2014)... November 21, 2014 2014 Deep ... professional and in-depth research report on the transformer ... definition, classification, application, and industry chain structure as ... international market analysis, including China’s domestic market as ... & economic situation analysis. The report also covers ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014  Cytori Therapeutics (NASDAQ: ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com on ... 2014 TIME:    11:15 am PT / 2:15 pm ... URL into your browser,s address bar: http://bit.ly/1B2KGaL ... and receive event updates. This will be ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... Silence Therapeutics plc,(AIM: SLN) today announces a collaboration ... a range of novel approaches for the delivery,of ... leading,expertise in the delivery of siRNA molecules, in ... siRNA in vivo using its,proprietary AtuPLEX technology. The ...
... Therapeutics, Inc.,( http://www.proteontherapeutics.com ), a privately held ... the,medical needs of patients with kidney and ... seasoned biopharmaceutical executive, to the Company,s,Board of ... years of executive,leadership and experience in the ...
... for Monday, March 17th at 11:30am ET, NEW ... ) today announced that I. Craig Henderson, MD, the,Company,s ... Affairs, are scheduled to present at the Cowen and ... presentation, which will take place on Monday, March 17th ...
Cached Biology Technology:Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 2Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 3Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors 2Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference 2
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
(Date:11/6/2014)... -- A groundbreaking paper from a team of Florida ... of how plants could adapt to and survive environmental ... published in the latest issue of the journal ... (the complex of DNA and proteins) is organized in ... that some genes are turned on and others are ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2
... Mich. We are all aware of the health benefits ... do we metabolize it? Research at the University of ... and institutions in Canada and Sweden, has begun to uncover ... in fruits and vegetables. Trillions of bacteria live in ...
... a scarred heart cannot beat the way it used to, ... heart, at least. A team of University of Michigan ... colonies of beating heart cells. Their findings could advance the ... attack. Previous work in direct reprogramming, jumping straight from ...
... in twenty years with the current poaching rates. The loss of ... have tremendous effects on the ecosystems they now live in. ... are key drivers of ecosystem functioning because theyre not controlled by ... Beest, published in Journal of Ecology , highlights the role ...
Cached Biology News:U-M scientists & colleagues investigate the fiber of our being 2Help for a scarred heart: Scarring cells turned to beating muscle 2Poaching threatens savannah ecosystems 2
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
... The pAcAB4 vector is a 10.0 ... that contains two,copies of the AcNPV polyhedrin ... of the first p10,promoter is a Sma ... termination sequences. Upstream of this,an inverted polyhedrin ...
BD BioCoat Osteologic Coverslips that have been sterilized by ETO gas. Coating : Osteologic&trade ,Thickness : 0.16 mm ,Diameter : 12.7 mm ,Gridded : No ...
Biology Products: